Daiken Medical Co (TSE:7775) EBIT: 円1,258 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7775 Daiken Medical Co Ltd TSE:7775
62 GF Score
Price 円426.00
GF Value 円541.84
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Daiken Medical Co EBIT?

Daiken Medical Co TSE:7775 +0.24% 62 EBIT is 円1,258 Mil as of Mar. 2026. GuruFocus rates TSE:7775 with a GF Score™ of 62/100 and a GF Value™ of 円541.84 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Daiken Medical Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円578 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,258 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Daiken Medical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 11.30%. Daiken Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Daiken Medical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.75%.

Daiken Medical Co  (TSE:7775) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Daiken Medical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1203.182 * ( 1 - 28.13% )/( (7811.737 + 7487.749)/ 2 )
=864.7269034/7649.743
=11.30 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10828.122 - 704.567 - ( 2311.818 - max(0, 2542.975 - 6538.578+2311.818))
=7811.737

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11366.782 - 1100.654 - ( 2778.379 - max(0, 2721.974 - 7028.268+2778.379))
=7487.749

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Daiken Medical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1156.694/( ( (4018.193 + max(2723.824, 0)) + (4043.839 + max(2923.66, 0)) )/ 2 )
=1156.694/( ( 6742.017 + 6967.499 )/ 2 )
=1156.694/6854.758
=16.87 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1125.569 + 1556.345 + 1544.846) - (704.567 + 0 + 798.369)
=2723.824

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1231.106 + 1591.946 + 1426.837) - (1100.654 + 0 + 225.575)
=2923.66

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Daiken Medical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1258.452/11709.834
=10.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiken Medical Co EBIT Related Terms

Daiken Medical Co EBIT Historical Data

* Premium members only.

The historical data trend for Daiken Medical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daiken Medical Co EBIT Chart

Daiken Medical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,155.07 1,028.99 1,441.28 1,517.79 1,258.45

Daiken Medical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 688.72 839.88 677.91 680.11 578.35

TSE:7775 vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Daiken Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiken Medical Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daiken Medical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Daiken Medical Co's EV-to-EBIT falls into.


TSE:7775
62GF Score
Daiken Medical Co Ltd TSE:7775
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daiken Medical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円1,258 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円1,258 Mil mean?
Daiken Medical Co (TSE:7775) has a EBIT of 円1,258 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Daiken Medical Co.
Is Daiken Medical Co's EBIT too high?
Daiken Medical Co's current EBIT is 円1,258 Mil. Overall, Daiken Medical Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiken Medical Co's EBIT compare to ISRG and BDX?
Daiken Medical Co's EBIT of 円1,258 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Daiken Medical Co. Daiken Medical Co's current EBIT is 円1,258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Daiken Medical Co (TSE:7775) is currently considered Modestly Undervalued. The stock's GF Value™ is 円541.84, compared to a current price of 円426.00 — trading 21.4% below its estimated fair value. The current EBIT is 円1,258 Mil. Daiken Medical Co's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Daiken Medical Co (TSE:7775), the current EBIT is 円1,258 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daiken Medical Co (TSE:7775) Overvalued in 2026?

Based on GuruFocus' analysis, Daiken Medical Co stock appears to be undervalued. The current stock price of 円426.00 is trading 21.4% below its estimated GF Value™ of 円541.84. GuruFocus considers Daiken Medical Co to be Modestly Undervalued.

Key valuation signals for TSE:7775:

  • EBIT: 円1,258 Mil
  • GF Value™: 円541.84 vs. price of 円426.00 (21.4% below fair value)
  • GF Score™: 62/100 with 1 warning sign

No single metric tells the full story. See the TSE:7775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daiken Medical Co Business Description

Address 3-6-1, Dosho-Machi, Chuo-Ku, Osaka, JPN, 541-0045
Daiken Medical Co Ltd manufactures and sells medical equipment. The product line includes - Coopdech syrinjector, Coopdech Syrinjector PCA device, Coopdech Balloonjector, Coopdech Endobronchial blocker tube, Coopdech double-lumen endobronchial tube, Fit fix suction container system, Wet disinfectant mat, and others.
62GF Score

Get the complete analysis for TSE:7775

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円426.00
Price
円541.84
GF Value